Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women

C. K. Cunningham, D. W. Wara, M. Kang, T. Fenton, E. Hawkins, J. McNamara, L. Mofenson, A. M. Duliege, D. Francis, E. J. McFarland, W. Borkowsky, T. Hastings, N. Deygoo, M. Lugo, M. Rivera, K. Contello, S. Nachman, M. Davi, C. R. Salbenblatt, M. J. Levin & 26 others R. Galvin, M. Mirochnick, A. Dorenbaum, S. A. Spector, W. M. Dankner, L. Frenkel, A. J. Melvin, K. M. Mohan, K. Mooney, C. Vincent, M. Silio, E. McBride, J. Pitt, P. LaRussa, E. G. Chadwick, D. F. Cloutier, J. Lambert, Nancy Hutton, B. Murante, S. Laverty, J. Sullivan, K. Luzuriaga, R. McKinney, M. Valentine, W. T. Shearer, M. Doyle

Research output: Contribution to journalArticle

Abstract

To determine the safety of 2 candidate vaccines against human immunodeficiency virus type 1 (HIV-1), a randomized, placebo-controlled, multicenter trial compared low, medium, and high doses of the vaccines or an adjuvant among infants born to HIV-infected women. No local or systemic reactions of grade 2 or greater were reported 48 h after the subjects underwent immunization. Grade 3 or 4 chemistry toxicities occurred in 5 (3%) and grade 3 or 4 hematologic toxicities in 17 (11%) of 154 vaccinated subjects (not significantly different from 29 adjuvant recipients). CD4+ cell percentages of ≤20% occurred at least once in 9 vaccinated subjects and 1 control subject. Sustained CD4+ cell percentages of ≤20% occurred in 4 HIV-infected children. Fourteen infants (8%) were confirmed to be HIV-infected; median CD4+ cell counts among these children were 2074, 1674, 1584, and 821 cells/mm3 at birth and weeks 24, 52, and 104, respectively. Thus, both vaccines were safe and well tolerated in neonates, and there was no evidence of accelerated immunologic decline in HIV-infected infants.

Original languageEnglish (US)
Pages (from-to)801-807
Number of pages7
JournalClinical Infectious Diseases
Volume32
Issue number5
DOIs
StatePublished - Mar 1 2001
Externally publishedYes

Fingerprint

HIV-1
Vaccines
HIV
Newborn Infant
Safety
CD4 Lymphocyte Count
Multicenter Studies
Immunization
Placebos
Parturition

ASJC Scopus subject areas

  • Immunology

Cite this

Cunningham, C. K., Wara, D. W., Kang, M., Fenton, T., Hawkins, E., McNamara, J., ... Doyle, M. (2001). Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clinical Infectious Diseases, 32(5), 801-807. https://doi.org/10.1086/319215

Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. / Cunningham, C. K.; Wara, D. W.; Kang, M.; Fenton, T.; Hawkins, E.; McNamara, J.; Mofenson, L.; Duliege, A. M.; Francis, D.; McFarland, E. J.; Borkowsky, W.; Hastings, T.; Deygoo, N.; Lugo, M.; Rivera, M.; Contello, K.; Nachman, S.; Davi, M.; Salbenblatt, C. R.; Levin, M. J.; Galvin, R.; Mirochnick, M.; Dorenbaum, A.; Spector, S. A.; Dankner, W. M.; Frenkel, L.; Melvin, A. J.; Mohan, K. M.; Mooney, K.; Vincent, C.; Silio, M.; McBride, E.; Pitt, J.; LaRussa, P.; Chadwick, E. G.; Cloutier, D. F.; Lambert, J.; Hutton, Nancy; Murante, B.; Laverty, S.; Sullivan, J.; Luzuriaga, K.; McKinney, R.; Valentine, M.; Shearer, W. T.; Doyle, M.

In: Clinical Infectious Diseases, Vol. 32, No. 5, 01.03.2001, p. 801-807.

Research output: Contribution to journalArticle

Cunningham, CK, Wara, DW, Kang, M, Fenton, T, Hawkins, E, McNamara, J, Mofenson, L, Duliege, AM, Francis, D, McFarland, EJ, Borkowsky, W, Hastings, T, Deygoo, N, Lugo, M, Rivera, M, Contello, K, Nachman, S, Davi, M, Salbenblatt, CR, Levin, MJ, Galvin, R, Mirochnick, M, Dorenbaum, A, Spector, SA, Dankner, WM, Frenkel, L, Melvin, AJ, Mohan, KM, Mooney, K, Vincent, C, Silio, M, McBride, E, Pitt, J, LaRussa, P, Chadwick, EG, Cloutier, DF, Lambert, J, Hutton, N, Murante, B, Laverty, S, Sullivan, J, Luzuriaga, K, McKinney, R, Valentine, M, Shearer, WT & Doyle, M 2001, 'Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women', Clinical Infectious Diseases, vol. 32, no. 5, pp. 801-807. https://doi.org/10.1086/319215
Cunningham, C. K. ; Wara, D. W. ; Kang, M. ; Fenton, T. ; Hawkins, E. ; McNamara, J. ; Mofenson, L. ; Duliege, A. M. ; Francis, D. ; McFarland, E. J. ; Borkowsky, W. ; Hastings, T. ; Deygoo, N. ; Lugo, M. ; Rivera, M. ; Contello, K. ; Nachman, S. ; Davi, M. ; Salbenblatt, C. R. ; Levin, M. J. ; Galvin, R. ; Mirochnick, M. ; Dorenbaum, A. ; Spector, S. A. ; Dankner, W. M. ; Frenkel, L. ; Melvin, A. J. ; Mohan, K. M. ; Mooney, K. ; Vincent, C. ; Silio, M. ; McBride, E. ; Pitt, J. ; LaRussa, P. ; Chadwick, E. G. ; Cloutier, D. F. ; Lambert, J. ; Hutton, Nancy ; Murante, B. ; Laverty, S. ; Sullivan, J. ; Luzuriaga, K. ; McKinney, R. ; Valentine, M. ; Shearer, W. T. ; Doyle, M. / Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. In: Clinical Infectious Diseases. 2001 ; Vol. 32, No. 5. pp. 801-807.
@article{7766a8a778c94244aafa4ada99b2791d,
title = "Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women",
abstract = "To determine the safety of 2 candidate vaccines against human immunodeficiency virus type 1 (HIV-1), a randomized, placebo-controlled, multicenter trial compared low, medium, and high doses of the vaccines or an adjuvant among infants born to HIV-infected women. No local or systemic reactions of grade 2 or greater were reported 48 h after the subjects underwent immunization. Grade 3 or 4 chemistry toxicities occurred in 5 (3{\%}) and grade 3 or 4 hematologic toxicities in 17 (11{\%}) of 154 vaccinated subjects (not significantly different from 29 adjuvant recipients). CD4+ cell percentages of ≤20{\%} occurred at least once in 9 vaccinated subjects and 1 control subject. Sustained CD4+ cell percentages of ≤20{\%} occurred in 4 HIV-infected children. Fourteen infants (8{\%}) were confirmed to be HIV-infected; median CD4+ cell counts among these children were 2074, 1674, 1584, and 821 cells/mm3 at birth and weeks 24, 52, and 104, respectively. Thus, both vaccines were safe and well tolerated in neonates, and there was no evidence of accelerated immunologic decline in HIV-infected infants.",
author = "Cunningham, {C. K.} and Wara, {D. W.} and M. Kang and T. Fenton and E. Hawkins and J. McNamara and L. Mofenson and Duliege, {A. M.} and D. Francis and McFarland, {E. J.} and W. Borkowsky and T. Hastings and N. Deygoo and M. Lugo and M. Rivera and K. Contello and S. Nachman and M. Davi and Salbenblatt, {C. R.} and Levin, {M. J.} and R. Galvin and M. Mirochnick and A. Dorenbaum and Spector, {S. A.} and Dankner, {W. M.} and L. Frenkel and Melvin, {A. J.} and Mohan, {K. M.} and K. Mooney and C. Vincent and M. Silio and E. McBride and J. Pitt and P. LaRussa and Chadwick, {E. G.} and Cloutier, {D. F.} and J. Lambert and Nancy Hutton and B. Murante and S. Laverty and J. Sullivan and K. Luzuriaga and R. McKinney and M. Valentine and Shearer, {W. T.} and M. Doyle",
year = "2001",
month = "3",
day = "1",
doi = "10.1086/319215",
language = "English (US)",
volume = "32",
pages = "801--807",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women

AU - Cunningham, C. K.

AU - Wara, D. W.

AU - Kang, M.

AU - Fenton, T.

AU - Hawkins, E.

AU - McNamara, J.

AU - Mofenson, L.

AU - Duliege, A. M.

AU - Francis, D.

AU - McFarland, E. J.

AU - Borkowsky, W.

AU - Hastings, T.

AU - Deygoo, N.

AU - Lugo, M.

AU - Rivera, M.

AU - Contello, K.

AU - Nachman, S.

AU - Davi, M.

AU - Salbenblatt, C. R.

AU - Levin, M. J.

AU - Galvin, R.

AU - Mirochnick, M.

AU - Dorenbaum, A.

AU - Spector, S. A.

AU - Dankner, W. M.

AU - Frenkel, L.

AU - Melvin, A. J.

AU - Mohan, K. M.

AU - Mooney, K.

AU - Vincent, C.

AU - Silio, M.

AU - McBride, E.

AU - Pitt, J.

AU - LaRussa, P.

AU - Chadwick, E. G.

AU - Cloutier, D. F.

AU - Lambert, J.

AU - Hutton, Nancy

AU - Murante, B.

AU - Laverty, S.

AU - Sullivan, J.

AU - Luzuriaga, K.

AU - McKinney, R.

AU - Valentine, M.

AU - Shearer, W. T.

AU - Doyle, M.

PY - 2001/3/1

Y1 - 2001/3/1

N2 - To determine the safety of 2 candidate vaccines against human immunodeficiency virus type 1 (HIV-1), a randomized, placebo-controlled, multicenter trial compared low, medium, and high doses of the vaccines or an adjuvant among infants born to HIV-infected women. No local or systemic reactions of grade 2 or greater were reported 48 h after the subjects underwent immunization. Grade 3 or 4 chemistry toxicities occurred in 5 (3%) and grade 3 or 4 hematologic toxicities in 17 (11%) of 154 vaccinated subjects (not significantly different from 29 adjuvant recipients). CD4+ cell percentages of ≤20% occurred at least once in 9 vaccinated subjects and 1 control subject. Sustained CD4+ cell percentages of ≤20% occurred in 4 HIV-infected children. Fourteen infants (8%) were confirmed to be HIV-infected; median CD4+ cell counts among these children were 2074, 1674, 1584, and 821 cells/mm3 at birth and weeks 24, 52, and 104, respectively. Thus, both vaccines were safe and well tolerated in neonates, and there was no evidence of accelerated immunologic decline in HIV-infected infants.

AB - To determine the safety of 2 candidate vaccines against human immunodeficiency virus type 1 (HIV-1), a randomized, placebo-controlled, multicenter trial compared low, medium, and high doses of the vaccines or an adjuvant among infants born to HIV-infected women. No local or systemic reactions of grade 2 or greater were reported 48 h after the subjects underwent immunization. Grade 3 or 4 chemistry toxicities occurred in 5 (3%) and grade 3 or 4 hematologic toxicities in 17 (11%) of 154 vaccinated subjects (not significantly different from 29 adjuvant recipients). CD4+ cell percentages of ≤20% occurred at least once in 9 vaccinated subjects and 1 control subject. Sustained CD4+ cell percentages of ≤20% occurred in 4 HIV-infected children. Fourteen infants (8%) were confirmed to be HIV-infected; median CD4+ cell counts among these children were 2074, 1674, 1584, and 821 cells/mm3 at birth and weeks 24, 52, and 104, respectively. Thus, both vaccines were safe and well tolerated in neonates, and there was no evidence of accelerated immunologic decline in HIV-infected infants.

UR - http://www.scopus.com/inward/record.url?scp=0035282250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035282250&partnerID=8YFLogxK

U2 - 10.1086/319215

DO - 10.1086/319215

M3 - Article

VL - 32

SP - 801

EP - 807

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -